North American monoclonal antibodies market is estimated to grow at a CAGR of 6.8% during the forecast period. Some pivotal factors encouraging market growth include a significant rise in cancer incidences and rising new FDA launches for monoclonal antibody drugs. Additionally, launches of monoclonal antibody biosimilars treatment are providing an opportunity for market growth. For instance, in January 2020, Pfizer launched three new biosimilars named rituximab-pvvr (Ruxience), trastuzumab-qyyp (Trazimera), and bevacizumab-bvzr (Zirabev) in the US. This is expected that the specialty drugs will be launched at the lowest wholesale acquisition cost (WAC) among trastuzumab, bevacizumab, or rituximab products currently on the market. These drugs will become available at a discounted price than their equivalents brand name.
This launch can support significant savings for the healthcare system in the US while enhancing access to vital therapies. Pfizer is looking forward to work with providers and payers to offer these essential medications to patients who are suffering from certain cancers and autoimmune conditions. These new biosimilars will enable healthcare providers to deliver additional treatment options for patients across 9 cancer forms, including metastatic colorectal cancer, recurrent, or metastatic cervical cancer, breast cancer, metastatic renal cell carcinoma, and others.
North American monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. In 2019, cancer held the largest share in the market owing to the increasing preference for monoclonal antibody drugs for cancer treatment in the region. It acts as a targeted and immunotherapy to find and destroy cancer cells. Additionally, an increasing number of clinical trials for cancer monoclonal antibodies is further anticipated to drive the market growth.
To Request a Sample of our Report on North American Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/north-american-monoclonal-antibodies-market
Monoclonal Antibodies Market-Segmentation
By Source
- Murine
- Chimeric
- Human
- Humanized
By Application
- Cancer
- Infectious Diseases
- Auto-Immune Diseases
- Inflammatory Diseases
- Others
A full Report of North American Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/north-american-monoclonal-antibodies-market
Regional Analysis
- United States
- Canada
Company Profiles
- AbbVie Inc.
- Amgen Inc.
- Aytu BioScience, Inc.
- Biocon Ltd.
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Hoffman La-Roche AG
- Gilead Sciences, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Mylan N.V.
- Oncologie, Inc.
- Pfizer Inc.
- Spectrum Pharmaceuticals, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/north-american-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
